The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.
Researchers at Sanofi and the NIH have published preclinical evidence showing that a three-pronged approach may prevent HIV in healthy people.
VC Lightstone has $250 million in the bank for life science research.
Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.
Arcus has signed a deal with Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand.
XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.
The clean sweep is a big win for Alnylam and the Sanofi-partnered RNAi drug, which is now set to be put before regulators at the end of the year.
Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.
Acceleron's collaboration with Celgene on sotatercept has taken another turn, giving Acceleron the right to develop the drug for pulmonary diseases.